{
    "clinical_study": {
        "@rank": "35158", 
        "acronym": "ARD", 
        "arm_group": [
            {
                "arm_group_label": "HO/02/02", 
                "arm_group_type": "Experimental", 
                "description": "Interventions involving HO/02/02 20\u00b5g VS. Aloe Vera Jel (SOC). Treatment will be applied topically once daily"
            }, 
            {
                "arm_group_label": "Aloe Vera Jel", 
                "arm_group_type": "Sham Comparator", 
                "description": "To be applied topically"
            }
        ], 
        "brief_summary": {
            "textblock": "This is a single-center, open-label, randomized, prospective study evaluating the safety and\n      efficacy of HO/02/02 20\u00b5g topically applied daily for 15 minutes (with gauze) on treatment\n      fields vs. standard of care (SoC),  Aloe Vera treatment"
        }, 
        "brief_title": "Safety and Efficacy of HO/02/02 20\u00b5g vs. SoC (Aloe Vera) to Reduce Radiation Dermatitis", 
        "completion_date": {
            "#text": "December 2014", 
            "@type": "Anticipated"
        }, 
        "condition": "Breast Cancer", 
        "condition_browse": {
            "mesh_term": [
                "Breast Neoplasms", 
                "Dermatitis", 
                "Radiodermatitis"
            ]
        }, 
        "detailed_description": {
            "textblock": "This is a single-center, open-label, randomized, prospective study evaluating the safety and\n      efficacy of HO/02/02 20\u00b5g topically applied daily for 15 minutes (with gauze) on treatment\n      fields vs. standard of care (SoC),  Aloe Vera treatment in addition to sterile water for\n      irrigation applied daily for 15 minutes (with gauze) on treatment fields to create the same\n      cooling effect as in treatment arm 1. Both treatment arms 1&2 treatments will be applied\n      topically once daily for up to 8 weeks to reduce radiation dermatitis in up to 90 breast\n      cancer patients undergoing  adjuvant radiation therapy."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Female patients 18 years old and above.\n\n          -  Histology confirmed unilateral breast cancer following lumpectomy\n\n          -  Planned to receive 50 Gy, whole breast XRT and regional lymph nodes  radiation.\n\n          -  ECOG performance status 0-2\n\n          -  Completed Chemotherapy 3 weeks prior to XRT (if applicable)\n\n          -  Patient should be available for the entire study period, and be able and willing to\n             adhere to protocol requirements;\n\n          -  Patient must sign an informed consent form prior to undergoing any study-related\n             procedures\n\n        Exclusion Criteria:\n\n          -  Known uncontrolled diabetes\n\n          -  Prior radiation to breast\n\n          -  Known connective tissue disorder\n\n          -  Known skin disease over the treated breast\n\n          -  Prior burn over treated area\n\n          -  Evidence of infection or inflammation of breast to be treated.\n\n          -  Receiving biological therapy or hormone therapy (other than Herceptin) during\n             radiation treatment/study duration and 4 weeks prior to study entry.\n\n          -  Pre-existing skin breakdown within the planned radiotherapy field at the time of\n             study entry.\n\n          -  Pregnancy, planned pregnancy, lactation or inadequate contraception as judged by the\n             Investigator.\n\n          -  Participation in another investigational drug or vaccine trial concurrently or within\n             30 days.\n\n          -  Use of any other topical or systemic treatments aimed at radiation dermatitis.\n\n          -  Use of a prescription or over-the-counter medication that contains hydrocortisone or\n             any other cortisone or corticosteroid containing preparation"
            }, 
            "gender": "Female", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "90", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "August 12, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01923220", 
            "org_study_id": "HO-ARD-01-2012"
        }, 
        "intervention": [
            {
                "arm_group_label": "HO/02/02", 
                "description": "Interventions involving HO/02/02 20\u00b5g VS. Aloe Vera Jel (SOC). Treatment will be applied topically once daily", 
                "intervention_name": "HO/02/02 20\u00b5g", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "Aloe Vera Jel", 
                "description": "To be applied topically once daily", 
                "intervention_name": "Aloe Vera Jel", 
                "intervention_type": "Other", 
                "other_name": "Aloe Vera Jel"
            }
        ], 
        "is_fda_regulated": "No", 
        "keyword": [
            "Breast Cancer", 
            "Radiation Therapy", 
            "Radiation Dermatitis"
        ], 
        "lastchanged_date": "August 12, 2013", 
        "location": {
            "contact": {
                "email": "ilanit_2@walla.com", 
                "last_name": "Ilanit Dromi", 
                "phone": "+972-544943210"
            }, 
            "facility": {
                "address": {
                    "city": "Ramat Gan", 
                    "country": "Israel", 
                    "zip": "52621"
                }, 
                "name": "The Chaim Sheba Medical Center"
            }, 
            "investigator": {
                "last_name": "Merav Ben-David, M.D.", 
                "role": "Principal Investigator"
            }, 
            "status": "Not yet recruiting"
        }, 
        "location_countries": {
            "country": "Israel"
        }, 
        "number_of_arms": "2", 
        "official_title": "An Open-Label, Randomized Study to Evaluate the Safety and Efficacy of HO/02/02 20\u00b5g vs. SoC (Aloe Vera) to Reduce Radiation Dermatitis In Breast Cancer Patients Undergoing Radiation Therapy.", 
        "overall_contact": {
            "email": "yair@healor.com", 
            "last_name": "Yair Alegranti", 
            "phone": "+972-8-9407188", 
            "phone_ext": "122"
        }, 
        "overall_contact_backup": {
            "email": "kira@healor.com", 
            "last_name": "Kira Olshvang", 
            "phone": "+972-8-9407188", 
            "phone_ext": "117"
        }, 
        "overall_official": {
            "affiliation": "HealOr", 
            "last_name": "Yair Alegranti", 
            "role": "Study Director"
        }, 
        "overall_status": "Not yet recruiting", 
        "oversight_info": {
            "authority": "Israel: The Israel National Institute for Health Policy Research and Health Services Research", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 0", 
        "primary_completion_date": {
            "#text": "September 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "measure": "Number of patients using HO/02/02 20\u00b5g that developed grade 1-4 radiation dermatitis during adjuvant radiation therapy for breast cancer compared to SoC (Aloe Vera) commonly used as standard of care treatment.", 
            "safety_issue": "No", 
            "time_frame": "62 days"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01923220"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": {
            "measure": "Frequency and severity of adverse events reported by the patients and assessed clinically by NCI CTC v2.0", 
            "safety_issue": "No", 
            "time_frame": "62 Days"
        }, 
        "source": "HealOr", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "HealOr", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "September 2013", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention", 
        "study_type": "Interventional", 
        "verification_date": "August 2013"
    }
}